Granupas

Granupas is a prescription oral medication that contains the active ingredient aminosalicylic acid. It is supplied in an unspecified strength and dosage form, and is marketed in the European Union. Aminosalicylic acid belongs to the antitubercular drug class and works by inhibiting folate synthesis in Mycobacterium tuberculosis, thereby interfering with bacterial growth. Granupas is used under medical supervision for the treatment of tuberculosis in patients.

Granupas is indicated for the management of active tuberculosis caused by Mycobacterium tuberculosis.

- First‑line therapy in combination with other antitubercular agents - Treatment of pulmonary TB - Treatment of extrapulmonary TB - Use in patients with drug‑sensitive TB strains - Part of multi‑drug regimens to prevent resistance - Adjunct therapy for patients who cannot tolerate isoniazid - Used in retreatment regimens where resistance to first‑line drugs is identified

Aminosalicylic acid may cause a range of adverse effects, most of which are mild and reversible.

Common: - Nausea or vomiting - Abdominal discomfort or diarrhea - Rash or mild skin irritation - Elevated liver enzymes (asymptomatic) - Loss of appetite - Headache - Metallic taste - Dizziness - Fatigue - Mouth ulcers

Serious: - Severe hepatic injury or hepatitis - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Interstitial nephritis - Severe hypersensitivity reactions - Blood dyscrasias - Seizures - Severe anemia - Cardiac arrhythmias - Renal failure

Most patients experience only mild symptoms, but clinicians monitor for signs of serious toxicity during therapy. Patients are advised to report any persistent gastrointestinal upset or skin changes promptly.

When prescribing Granupas, clinicians consider several precautionary measures to ensure safe use and to minimize risk of adverse outcomes.

- Assess liver function before initiating therapy and monitor periodically. - Evaluate complete blood count, especially neutrophil levels, during treatment. - Use caution in patients with pre‑existing renal impairment. - Avoid use in individuals with known hypersensitivity to aminosalicylic acid or related salicylates. - Consider potential interactions with other antitubercular drugs that affect hepatic metabolism. - Pregnant or breastfeeding women should be evaluated by a specialist before use. - Discontinue if signs of severe hepatic or hematologic toxicity appear.

Aminosalicylic acid can interact with several medications, affecting its efficacy or increasing the risk of toxicity.

Avoid: - Concurrent use with high-dose aspirin or other salicylates, which may increase the risk of gastrointestinal bleeding. - Co‑administration with hepatotoxic drugs such as isoniazid, rifampicin, or pyrazinamide, which can exacerbate liver injury. - Combining with drugs that cause bone marrow suppression, such as linezolid, may potentiate hematologic toxicity.

Use with caution: - Use with other antitubercular agents that are metabolized by the liver; dose adjustments may be needed. - Caution when taken with anticoagulants (e.g., warfarin) as salicylates can affect clotting parameters. - Monitor renal function when combined with nephrotoxic agents like aminoglycosides. - Consider potential interaction with antiretroviral therapy in HIV‑co‑infected patients.